BMS receives EU approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the treatment of malignant mesothelioma
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment ...
Read more